A Study of Immunotherapy Treatment in People With Sarcoma

Memorial Sloan Kettering Cancer Center (MSK)

Status: Invitation-only

Conditions: Sarcoma

Study type: Observational

Funder types: Other

Identifiers

NCT06113315

23-254

Details and patient eligibility

About

The purpose of this study is to collect information from participants' medical records to improve our knowledge about immunotherapy use and how effective it is as a treatment for people with sarcoma. Immunotherapy drugs boost the immune system's ability to fight cancer by blocking proteins that act as a "brake" on the immune system. Blocking these proteins is like releasing the brakes, so that the immune system can target cancer cells and destroy them. This action is sometimes described as "immune checkpoint blockade.

Enrollment: 250 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist.
• Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll

Exclusion criteria

• Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB initiation), during, and after ICB treatment

Trial design

250 participants in 1 patient group

patients with sarcoma

Description:

This is an observational prospective cohort study of patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1, and/or CTLA-4) based therapy at Memorial Sloan Kettering Cancer Center (MSK)